JP2023501308A - 抗ミュラー管ホルモンポリペプチド - Google Patents

抗ミュラー管ホルモンポリペプチド Download PDF

Info

Publication number
JP2023501308A
JP2023501308A JP2022525870A JP2022525870A JP2023501308A JP 2023501308 A JP2023501308 A JP 2023501308A JP 2022525870 A JP2022525870 A JP 2022525870A JP 2022525870 A JP2022525870 A JP 2022525870A JP 2023501308 A JP2023501308 A JP 2023501308A
Authority
JP
Japan
Prior art keywords
amh
seq
amino acid
sequence
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525870A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021081601A5 (https=
JP2023501308A5 (https=
Inventor
クレイグ・アンソニー・ハリスン
ケリー・ルイーズ・ウォルトン
Original Assignee
モナシュ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904097A external-priority patent/AU2019904097A0/en
Application filed by モナシュ ユニバーシティ filed Critical モナシュ ユニバーシティ
Publication of JP2023501308A publication Critical patent/JP2023501308A/ja
Publication of JPWO2021081601A5 publication Critical patent/JPWO2021081601A5/ja
Publication of JP2023501308A5 publication Critical patent/JP2023501308A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022525870A 2019-10-30 2020-10-30 抗ミュラー管ホルモンポリペプチド Pending JP2023501308A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904097 2019-10-30
AU2019904097A AU2019904097A0 (en) 2019-10-30 Anti-mullerian hormone polypeptides
PCT/AU2020/051187 WO2021081601A1 (en) 2019-10-30 2020-10-30 Anti-mullerian hormone polypeptides

Publications (3)

Publication Number Publication Date
JP2023501308A true JP2023501308A (ja) 2023-01-18
JPWO2021081601A5 JPWO2021081601A5 (https=) 2023-11-09
JP2023501308A5 JP2023501308A5 (https=) 2023-11-09

Family

ID=75714709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525870A Pending JP2023501308A (ja) 2019-10-30 2020-10-30 抗ミュラー管ホルモンポリペプチド

Country Status (8)

Country Link
US (1) US20220411477A1 (https=)
EP (1) EP4051699A4 (https=)
JP (1) JP2023501308A (https=)
KR (1) KR20220155980A (https=)
CN (1) CN114945588A (https=)
AU (1) AU2020373165A1 (https=)
CA (1) CA3156607A1 (https=)
WO (1) WO2021081601A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049960A1 (en) * 2023-08-30 2025-03-06 University Of Cincinnati Enhancing the production of anti-mullerian hormone through modification of its prodomain
WO2025085972A1 (en) * 2023-10-27 2025-05-01 Monash University Anti-mullerian hormone agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017290A1 (en) * 2008-08-05 2010-02-11 The Trustees Of Columbia University In The City Of New York Müllerian inhibiting substance (mis) analogues
WO2017216334A1 (fr) * 2016-06-17 2017-12-21 bioMérieux Procédé de préparation d'anticorps anti-amh et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012357A2 (en) * 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
CA2837472A1 (en) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
AU2013342190B2 (en) * 2012-11-09 2018-11-08 Ansh Labs Llc Antibody compositions and immunoassay methods to detect isoforms of Anti-Mullerian Hormone
US11230583B2 (en) * 2015-11-26 2022-01-25 Hudson Institute of Medical Research Inhibin analogs
WO2018112168A1 (en) * 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
US11261225B2 (en) * 2017-02-10 2022-03-01 Institute For Cancer Research Chimera of bone morphogenic protein 2 and the Müllerian-inhibiting substance type II receptor binding region of Müllerian-inhibiting substance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017290A1 (en) * 2008-08-05 2010-02-11 The Trustees Of Columbia University In The City Of New York Müllerian inhibiting substance (mis) analogues
WO2017216334A1 (fr) * 2016-06-17 2017-12-21 bioMérieux Procédé de préparation d'anticorps anti-amh et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GORDON, V. M. ET AL., INFECTION AND IMMUNITY, vol. 63, no. 1, JPN6024052150, 1995, pages 82 - 87, ISSN: 0005636503 *
JOHNSON, KATHARINE E. ET AL., MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 422, JPN6024052149, 2016, pages 84 - 92, ISSN: 0005636504 *

Also Published As

Publication number Publication date
US20220411477A1 (en) 2022-12-29
KR20220155980A (ko) 2022-11-24
CN114945588A (zh) 2022-08-26
WO2021081601A1 (en) 2021-05-06
AU2020373165A1 (en) 2022-05-26
CA3156607A1 (en) 2021-05-06
EP4051699A1 (en) 2022-09-07
EP4051699A4 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
JP7488303B2 (ja) ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法
JP2002543837A (ja) 組換えセトマンナン結合性レクチン
PL207588B1 (pl) Peptyd NTP, środek zawierający ten peptyd i zastosowanie tego peptydu
CN107427574A (zh) Cxcr4结合分子
EP2328917B1 (en) Neuronal viability factor and use thereof
JP2018510214A (ja) 二重シグナル伝達タンパク質（ｄｓｐ）融合タンパク質、及び疾患を処置するためのその使用方法
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
JP2020527331A (ja) Ｃ３ｂ不活性化ポリペプチド
JP2023501308A (ja) 抗ミュラー管ホルモンポリペプチド
US11603387B2 (en) SOCS mimetics for the treatment of diseases
US20070287826A1 (en) Production of high molecular mass lectins
CN111601815A (zh) 靶向细胞中c-Myc的嵌合分子
US20140288010A1 (en) Compositions and Methods for Increasing Stem Cell Survival
CN107412729A (zh) 用于治疗肾病综合征和有关病症的方法
KR102221041B1 (ko) 신증후군 및 관련 병태의 치료 방법
US9611314B2 (en) Functional peptide analogs of PEDF
US9139629B2 (en) Methods for treatment of nephrotic syndrome and related conditions
TW202417033A (zh) 腎臟結石的治療或預防劑
US8138304B2 (en) Neural regeneration peptides and formulations thereof
WO2025085972A1 (en) Anti-mullerian hormone agonists
TW201534725A (zh) 抑制熱休克蛋白質表現之胜肽及包含其之組成物
JP7375163B2 (ja) Ｔｇｆ－ベータトラップ
WO2026035333A1 (en) The skeletal muscle fusogen myomerger as a contributor to sperm:egg fusion
TW200927162A (en) Pharmaceutical compositions for treating diseases associated with angiogenesis and inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250708